STOCK TITAN

TWST insider Form 4: 29,518 PSUs credited; holdings 128,228

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Twist Bioscience (TWST): Form 4 insider update. Company officer Dennis Cho reported acquisition of 29,518 shares of common stock on 10/28/2025 at a price of $0, reflecting Performance Stock Units (PSUs) with target criteria determined to be met. Following this transaction, beneficial ownership stands at 128,228 shares, held directly.

The filing notes that 60% of these PSUs remain subject to time-based vesting and are scheduled to vest on October 1, 2026, contingent on continued service or potential acceleration under the award agreement. Role: Senior Vice President, Chief Legal Officer & Corporate Secretary.

Positive

  • None.

Negative

  • None.

Insights

Routine Form 4 reflecting PSU achievement; neutral impact.

The report shows an officer received 29,518 shares at $0 after PSU targets were met on October 28, 2025. This is standard equity compensation mechanics rather than an open-market purchase.

Post-transaction holdings total 128,228 shares, with 60% of the PSUs still time-based and scheduled to vest on October 1, 2026, contingent on continued service or potential acceleration under the award terms.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cho Dennis

(Last) (First) (Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/28/2025 A 29,518(1) A $0 128,228 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents Performance Stock Units for which target criteria was determined to have been met on October 28, 2025. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration of vesting as provided in the award agreement.
Remarks:
Senior Vice President, Chief Legal Officer & Corporate Secretary
/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho 10/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TWST’s insider report on Form 4?

An officer acquired 29,518 common shares on 10/28/2025 at $0, tied to PSUs whose target criteria were met.

How many TWST shares does the insider now hold?

Beneficial ownership is 128,228 shares, held directly after the reported transaction.

What are the vesting terms mentioned for the PSUs at TWST?

60% of the PSUs remain time-based and are scheduled to vest on October 1, 2026, subject to continued service or acceleration per the award agreement.

Who is the reporting person at TWST and their role?

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary.

What triggered the share acquisition reported by TWST’s insider?

The target criteria for Performance Stock Units were determined to have been met on 10/28/2025.

Was cash paid for the acquired TWST shares?

The transaction shows a price of $0, consistent with PSU settlement upon meeting targets.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

2.53B
60.26M
1.86%
115.89%
16.96%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO